Molecular and Cellular Biology, May 1999, p. 3496-3505, Vol. 19, No. 5
0270-7306/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Division of Hematology,
Received 15 December 1998/Returned for modification 3 February
1999/Accepted 12 February 1999
The transcription factor GATA-1 is a key regulator of
erythroid-cell differentiation and survival. We have previously shown that the transcriptional cofactor CREB-binding protein (CBP) binds to
the zinc finger domain of GATA-1, markedly stimulates the
transcriptional activity of GATA-1, and is required for erythroid
differentiation. Here we report that CBP, but not p/CAF, acetylates
GATA-1 at two highly conserved lysine-rich motifs present at the
C-terminal tails of both zinc fingers. Using [3H]acetate
labelling experiments and anti-acetyl lysine immunoprecipitations, we
show that GATA-1 is acetylated in vivo at the same sites acetylated by
CBP in vitro. In addition, we show that CBP stimulates GATA-1 acetylation in vivo in an E1A-sensitive manner, thus establishing a
correlation between acetylation and transcriptional activity of GATA-1.
Acetylation in vitro did not alter the ability of GATA-1 to bind DNA,
and mutations in either motif did not affect DNA binding of GATA-1
expressed in mammalian cells. Since certain functions of GATA-1 are
revealed only in an erythroid environment, GATA-1 constructs were
examined for their ability to trigger terminal differentiation when
introduced into a GATA-1-deficient erythroid cell line. We found that
mutations in either acetylation motif partially impaired the
ability of GATA-1 to induce differentiation while mutations in both
motifs abrogated it completely. Taken together, these data indicate
that CBP is an important cofactor for GATA-1 and suggest a novel
mechanism in which acetylation by CBP regulates GATA-1 activity in
erythroid cells.
Erythrocyte development is among the
best-studied model systems used to define the mechanisms responsible
for lineage commitment, cellular differentiation, and tissue-specific
gene expression. The lineage-restricted transcription factor GATA-1
orchestrates several key aspects of erythroid development. Functionally
important binding sites for GATA-1 are found in the regulatory regions
of essentially all erythroid-cell-specific genes (30). Mice
deficient for GATA-1 succumb to fatal anemia due to an inability of
erythroid precursor cells to survive and mature (14, 43,
44). In addition, GATA-1 induces terminal erythroid maturation
when introduced into the GATA-1-deficient erythroid cell line G1E
(45).
Tissue-specific gene expression is the result of a concerted action of
tissue-restricted and ubiquitous transcription factors. Our previous
studies indicated that a widely expressed transcriptional cofactor,
CREB-binding protein (CBP), is a potent coactivator of GATA-1
(4). CBP associates with GATA-1 in vitro and in vivo and
markedly stimulates its activity. Expression of the adenovirus oncoprotein E1A, which interferes with the action of CBP, blocks the
effects of CBP on GATA-1 activity, inhibits erythroid differentiation, and reduces the expression of several GATA-1-dependent genes
(4).
Multiple mechanisms have been invoked to account for the activity of
CBP and its close relative p300. First, CBP interacts with TFIIB
(23), TATA-binding protein (1, 12, 37, 40), and
RNA polymerase II (10, 21, 27) and could thus serve as a
bridging molecule between DNA-bound transcription factors and the basal
transcription machinery. Second, CBP interacts with numerous
transcription factors via dedicated domains and could thus provide a
scaffold for the assembly of a high-molecular-weight "enhanceosome"
complex (for a review, see reference 38). Such multifunctional interactions may account for the observed synergy between transcription factors that use CBP and p300 as cofactors. Third, CBP and p300 possess intrinsic and associated histone
acetyltransferase activity (3, 9, 28, 39, 46). Acetylated
histones are associated with an open chromatin configuration, which in
turn might facilitate the accessibility of DNA to other transcription factors (for a review, see references 31 and
35). Finally, CBP and p300 were recently shown to
acetylate nonhistone proteins such as the tumor suppressor protein p53
(16), the erythroid Kruppel-like factor (EKLF)
(48), and the basal transcription factors, TFIIE and TFIIF
(19). In the case of p53, acetylation of the regulatory
domain led to a dramatic increase in DNA binding (16) in
vitro, whereas the functional consequences of EKLF, TFIIE, and TFIIF
acetylation remain to be explored.
In this report, we further define the mechanisms of transcriptional
activation of GATA-1 by CBP. We found that CBP acetylates GATA-1 at two
highly conserved lysine-rich motifs near the zinc finger domains. In
contrast to a recent report which appeared while this paper was under
review (7), we found that acetylation of GATA-1 did not
affect its ability to bind DNA and that substitutions or deletions in
these motifs did not affect DNA binding of mammalian-cell-expressed GATA-1. We also found that mutations in the C-terminal acetylation motif, but not in the N-terminal motif, reduce the binding to CBP and
diminish the response to CBP in transient-transfection assays. We
further demonstrate that CBP stimulates GATA-1 acetylation in vivo and
that coexpression of E1A abolishes GATA-1 acetylation.
Certain functions of GATA-1 critically depend on an erythroid
environment. For example, the N-terminal zinc finger of GATA-1 is
required for function in erythroid cells but is dispensable for
transactivation of some GATA-1-dependent reporter constructs in
transiently transfected NIH 3T3 cells (45). Conversely, a potent activation domain at the N terminus of GATA-1 is required for
transactivation in the NIH 3T3 cell assay while this domain is
dispensable for function in erythroid and megakaryocytic cells (6,
25, 42, 45). Therefore, we examined the function of the
acetylation sites in an assay that measures GATA-1 activity by its
ability to trigger terminal differentiation when introduced into the
GATA-1-deficient erythroid-cell line G1E. This assay revealed that
mutations in either motif reduce GATA-1 function without affecting its
ability to bind DNA. These results indicate that the acetylated motifs
are of biological importance independent of a role in DNA binding. They
further suggest that acetylation of GATA-1 might provide a novel
mechanism of controlling GATA-1 activity.
Plasmids.
Vectors expressing CBP (pCMV5-CBP) (a gift from M. Rosenfeld), GATA-1 (pXM-G1), E1A (pEF1 Acetylation site mapping.
Peptides corresponding to residues
236 to 255 and 304 to 323 of murine GATA-1 were synthesized with an
Applied Biosystems 430A synthesizer. The purity was estimated to be
85% based on high-pressure liquid chromatography (HPLC) analysis.
Twenty micrograms of peptide was incubated with 1 µg of GST-CBP-HAT
at 30°C for 2 h in 60 µl of acetyltransferase reaction buffer
(50 mM Tris-HCl [pH 8], 10% glycerol, 50 mM NaCl, 2.5 mM
MgCl2, 10 mM sodium butyrate, 0.5 mM dithiothreitol
[DTT], 0.5 mM phenylmethylsulfonyl fluoride [PMSF], 0.08 µCi of
[14C]acetyl coenzyme A [CoA]). The peptide was
separated from GST-CBP-HAT and free [14C]acetyl-CoA by
reverse-phase HPLC. Acetylated peptide was subjected to Edman
degradation; the first three cycles were used to confirm the amino acid
sequence, and the remaining cycles were collected for measurement of
14C incorporation by scintillation counting.
In vivo sodium [3H]acetate labeling and
immunoprecipitation experiments.
Twenty million exponentially
growing MEL cells were centrifuged and resuspended in 2 ml of medium
containing 1 mCi of sodium [3H]acetate per ml (16 Ci/mmol; ICN) and 50 nM Trichostatin (Sigma) and incubated for 90 min.
The cells were lysed in 350 mM NaCl-50 mM Tris-HCl (pH 7.5)-0.5%
Igepal-1 mM EDTA-0.5 mM DTT-10 mM sodium butyrate-1 µg of
aprotinin per ml-1 µg of pepstatin per ml-1 µg of leupeptin per
ml-0.2 mM PMSF. Following centrifugation at 10,000 × g for 5 min, the supernatants were diluted to 150 mM NaCl with H2O containing 1 mM EDTA, 0.5 mM DTT, 10 mM sodium
butyrate, 1 µg of aprotinin per ml, 1 µg of pepstatin per ml, 1 µg of leupeptin per ml, and 0.2 mM PMSF and immunoprecipitated with
monoclonal GATA-1 antibodies (N6; Santa Cruz) or irrelevant
isotype-matched antibodies. The antibodies were captured by adding 30 µl of a 50% slurry of protein G-Sepharose. Immunoprecipitated
samples were washed five times in 150 mM NaCl-50 mM Tris-HCl (pH
7.5)-0.5% Igepal-1 mM EDTA-0.5 mM DTT-10 mM sodium butyrate-1
µg of aprotinin per ml-1 µg of pepstatin per ml-1 µg of
leupeptin per ml-0.2 mM PMSF, resolved by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, fixed, enhanced with
Autofluor (National Diagnostics), and autoradiographed.
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-E1A), and GATA-1 reporter
construct M1
GH have been described previously (20, 25).
To construct CBP HAT
(a histone acetyltransferase
[HAT]-deficient version of CBP), Leu1690 and Cys1691 were changed to
Lys1690 and Leu1691 by overlapping PCR (22). The retroviral
construct expressing GATA-1, MFG-GATA-1, and various
glutathione-S-transferase (GST)-GATA-1 fusion constructs have been described previously (11, 45). GST-CBP-HAT
containing the HAT domain of murine CBP (amino acids [aa] 1196 to
1718) (3) was generated by cloning a PCR-amplified fragment
into pGEX4T. GST-p/CAF-HAT (a gift from M. Montminy) contains the HAT
domain of human p/CAF (46) (aa 352 to 832). To introduce
Lys-to-Ala mutations into the acetylation motifs of GATA-1, overlapping
PCR was used. Sequence analysis confirmed the absence of PCR errors. The N-terminal acetylation motif (LIRPKKRMIVSKRA; aa 241 to
254) was mutated to LIRAARMIVSKRA (N-mut). The C-terminal
motif (KASGKGKKKRGSNLAG; aa 308 to
323) was mutated to KASGAGAAARGSNLAG (C-mut).
In the construct termed NC-mut, both motifs were mutated. The mutant GATA-1 constructs were inserted into pXM, pGEX2T, MFG, and pBluescript.
Retroviral infections. BOSC23 cells (a gift from W. Pear) (32) were used to generate retrovirus harboring GATA-1 cRNAs. BOSC23 cells grown in T25 flasks to 80% confluence were transiently transfected with 8 µg of DNA per flask by the calcium phosphate precipitation method in the presence of 25 µM chloroquine. Fresh medium was added 10 h following transfection. At 24 h later, G1E cells (1.5 × 106/flask) were cocultivated with virus-producing BOSC23 cells for 42 h. Infected G1E cells were transferred to fresh medium and grown for an additional 48 h before being subjected to benzidine staining of hemoglobin (45).
Transient transfections, gel shift assays, and GST pull-down experiments. Transient transfections, gel shift assays, and GST pull-down experiments were performed as described previously (5, 11).
Acetyltransferase assays. Acetyltransferase assays were performed exactly as reported by Bannister and Kouzarides (3).
| |
RESULTS |
|---|
|
|
|---|
CBP acetylates GATA-1 at two conserved lysine-rich motifs. We have previously shown that CBP interacts with GATA-1 and stimulates its activity (4). GATA-1 contains two lysine-rich motifs located just C-terminal to each of its two zinc fingers, referred to below as the N-motif and C-motif. These motifs, which are highly conserved among GATA-1 proteins from different species and among other members of the GATA family (Fig. 1), are very similar to a sequence found in the C terminus of p53 which is directly acetylated by p300 (16) (Fig. 1). This raised the possibility that CBP also acetylates GATA-1. Indeed, the bacterially expressed HAT domain of CBP (CBP-HAT) acetylates full-length recombinant GST-GATA-1 but not GST alone (Fig. 2). Acetylation occurs with an efficiency comparable to that of histones (results not shown), and scintillation counting indicates an average incorporation of two [14C]acetate molecules per GATA-1 molecule (results not shown). Deletion of the zinc finger region, which removes both lysine-rich motifs (aa 198 to 316), abolishes acetylation while the isolated finger region (aa 177 to 333) is acetylated as strongly as wild-type GATA-1 (Fig. 2). Therefore, little or no acetylation occurs outside the zinc finger region. To determine whether the conserved lysine-rich motifs are the actual sites of acetylation, we replaced lysines with alanines in either motif alone or in combination. Since acetylation of p53 by CBP involved all three lysines in its KXKK motif (16), we began by replacing all the lysine residues in the lysine-rich motifs of GATA-1. Substitutions in the N-terminal motif (N-mut) or the C-terminal motif (C-mut) reduced acetylation to 50 to 60% of the wild-type level, as determined by phosphorimager analysis, while substitutions in both motifs (NC-mut) abrogated acetylation almost completely (Fig. 2); the residual acetylation is most probably attributable to lysine 252 next to the N-motif (see below).
|
|
|
In vivo acetylation of GATA-1. To determine whether acetylation of GATA-1 occurs in vivo, we pulse-labeled MEL cells with [3H]acetate for 90 min and then subjected them to cell lysis and immunoprecipitation with monoclonal GATA-1 antibodies. The autoradiograph shown in Fig. 4A demonstrates that GATA-1 antibodies, but not isotype-matched control antibodies, precipitate [3H]acetate-labelled GATA-1, indicating that acetylation of GATA-1 occurs in intact erythroid cells. Similar results were obtained with [3H]acetate-labelled COS cells transfected with GATA-1 (data not shown). A large number of cellular proteins are acetylated at their N terminus, which could account at least in part for the observed [3H]acetate incorporation. To ensure that acetylation of GATA-1 occurs in vivo at the same sites acetylated by CBP in vitro, we used an antibody, anti-AK, which reacts with acetyl-lysine residues but not with unacetylated lysine residues (18). Lysates from transfected COS cells were immunoprecipitated with anti-AK and then subjected to Western blotting with anti-GATA-1 antibodies. Anti-AK precipitated significant amounts of wild-type GATA-1 (Fig. 4B, top), while precipitation of N-mut and C-mut was reduced and only very little NC-mut was precipitated (Fig. 4B, top). Control Western blots demonstrate the presence of comparable amounts of transfected GATA-1 constructs in the lysates used for immunoprecipitation (Fig. 4B, bottom). These results indicate that GATA-1 is acetylated in vivo at the same sites acetylated by CBP in vitro. In addition, both lysine-rich motifs appear to contribute equally to total acetylation, again similar to what is observed with in vitro-acetylated GATA-1. As in the in vitro acetylation experiments, residual acetylation observed with NC-mut might be due to acetylation of lysine 252.
|
2-36), abolished in vivo acetylation of GATA-1
(Fig. 4C). Control Western blots showed that neither CBP nor E1A
expression significantly altered GATA-1 protein levels (data not
shown). This establishes a strong correlation between acetylation of
GATA-1 and its transcriptional activity (4).
The failure to detect acetylated GATA-1 in NIH 3T3 cells in the absence
of cotransfected CBP is due to the presence of substantially lower
basal levels of acetylated GATA-1 protein than in COS cells (data not shown).
Acetylation does not affect DNA binding of GATA-1. In contrast to p53, where acetylation occurs outside the DNA-binding domain (16), the acetylation motifs in GATA-1 are directly adjacent to the two zinc fingers (Fig. 1). Since acetylation leads to a change in the charge and size of the lysine residues, it seemed possible that acetylation results in altered DNA binding of GATA-1 (25). We tested this possibility in gel mobility shift assays with bacterially expressed GST-GATA-1 finger constructs acetylated in vitro. As shown in Fig. 5A, there was no detectable difference in DNA binding upon acetylation of the GATA-1 fingers over a broad range of protein concentrations. Similar results were obtained when full-length GST-GATA-1 was used (data not shown). As noted above, in vitro acetylation of GATA-1 occurred at high efficiency with incorporation of approximately two acetate residues per GATA-1 molecule. Therefore, it is unlikely that the failure to detect a difference in DNA binding is due to substoichiometric acetylation of GATA-1.
|
The C-terminal acetylation motif of GATA-1 is required for binding to and stimulation by CBP in transient-transfection assays. To test whether acetylation by CBP affects transcriptional activity of GATA-1, we cotransfected GATA-1 acetylation mutants together with CBP and a synthetic GATA site-containing reporter plasmid into NIH 3T3 cells. CBP expression increased wild-type GATA-1 and N-mut activity about eightfold, in agreement with our previous studies (Fig. 6A) (4). In contrast, C-mut and NC-mut were severely impaired in their response to CBP. Since CBP interacts with the zinc finger region of GATA-1 (4), we considered the possibility that mutations in the C-terminal motif affect interaction with CBP. To address this question, we performed in vitro protein-binding assays with bacterially expressed GST-CBP containing the GATA-1-binding domain (aa 1805 to 1891) and in vitro-translated GATA-1 constructs. The results show that C-mut and NC-mut bind GST-CBP less avidly than wild-type GATA-1 and N-mut do (Fig. 6B). This establishes a correlation between the ability of CBP to bind to GATA-1 and to enhance its activity, indicating that a direct interaction between these molecules is required for transcriptional stimulation.
|
), which
completely abolishes in vitro acetylation of free histones (22) and GST-GATA-1 (results not shown). In
transient-transfection assays, CBP-HAT
activated GATA-1
to the same extent as wild-type CBP did (Fig. 6C). Similar results were
obtained with a CBP construct bearing a deletion in the
acetyltransferase domain (
1458-1475) (reference 26 and data not shown). Thus, in
transient-transfection assays of nonerythroid cells with an artificial
reporter construct, GATA-1 activation by CBP does not require intrinsic
acetyltransferase activity of CBP. This suggests that acetylation might
be mediated by other acetyltransferases associated with CBP or that
GATA-1 activation might involve an acetylation-independent mechanism (see Discussion).
The following additional considerations have to be made when assaying
GATA-1 and CBP functions. First, the chromatin structure of stably
integrated genes regulated by GATA-1 and CBP is likely to be important,
especially when evaluating the role of histone and factor acetylation.
Second, regulation of GATA-1 and CBP activity might require the
architecture of natural GATA-1-dependent gene promoters. Third, it is
established that some GATA-1 functions are critically dependent on an
erythroid environment (see below). To address these issues, we used the
GATA-1-deficient erythroid cell line G1E, which can be induced to
terminally differentiate upon introduction of GATA-1.
Both N and C acetylation motifs are required to trigger erythroid
differentiation.
GATA-1-deficient G1E cells proliferate as
immature erythroblasts and undergo terminal differentiation and
hemoglobinization upon infection with GATA-1-expressing retrovirus
(45). Previous structure-function studies of GATA-1 yielded
important differences in domain requirements depending on whether these
studies were performed with NIH 3T3 cells or in G1E cells (25,
45) (see the introduction). To assess the role of GATA-1
acetylation in an erythroid context with chromatinized GATA-1 target
genes, we determined the ability of various GATA-1 mutants to induce
G1E cell differentiation. Retroviruses harboring wild-type and mutant GATA-1 constructs were used to infect G1E cells, and the extent of
erythroid differentiation was monitored by benzidine staining for
hemoglobin. Infection with wild-type GATA-1-carrying virus induced
hemoglobinization in about 7% of cells, which approximates the
proportion of infected cells, similar to what has been reported previously (45). The number of benzidine-positive cells
obtained with GATA-1 was used as a standard (100%) against which to
compare the other GATA-1 constructs. A substantially reduced number of benzidine-positive cells was seen when either N-mut or C-mut was expressed (10% and 22% of wild-type levels, respectively) (Fig. 7A), while NC-mut was completely
inactive, with no detectable benzidine-positive cells. Consistent with
these findings, a GATA-1 mutant which lacks the entire C terminus
(
308, residues 308 to 413 deleted), including the C-terminal
acetylation motif, showed an activity comparable to that of C-mut (Fig.
7A). In contrast, a similar deletion construct (
331, residues 331 to
413 deleted) which leaves the C motif intact was almost as active as
wild-type GATA-1. A non-DNA-binding mutant of GATA-1, which bears a
mutation in the C-terminal zinc finger (C261P) (25), showed
no activity in this assay (Fig. 7A). To confirm that expression levels
and DNA binding of all GATA-1 constructs were comparable in erythroid cells, nuclear extracts were prepared from the infected G1E cells and
analyzed by gel mobility shift assays with a GATA-1-binding site as
probe. To distinguish GATA-1 from endogenous GATA-2, which migrates at
a similar position, monoclonal anti-GATA-1 antibodies were used to
generate a GATA-1-specific supershift. The amounts of GATA-1
supershifted with GATA-1 antibodies were comparable in all samples
(Fig. 7B). Together, these experiments establish the requirement of
both acetylation motifs for GATA-1 activity in erythroid cells. These
results contrast with those obtained in NIH 3T3 cells, where mutations
at the N-motif had no detectable effect, and underscore the importance
of the cellular environment for the analysis of transcription factor
activity.
|
| |
DISCUSSION |
|---|
|
|
|---|
It has long been known that acetylated histones are associated
with transcriptionally active chromatin (2, 33). A strong correlation between histone acetylation and DNase I sensitivity has
been demonstrated at the chicken
globin gene (17).
Moreover, a number of transcription factors have recently been added to the list of acetyltransferase substrates (16, 19, 48). We have previously shown that the HAT CBP physically interacts with GATA-1
and stimulates its activity in an E1A-sensitive manner (4).
Interference with CBP function by forced expression of E1A led to a
block in erythroid differentiation and failure to induce
GATA-1-dependent genes, including the
- and
-globin genes. Deletion of the N-terminal 23 aa of E1A, which abrogates binding to
CBP/p300 but not to Rb family proteins, led to loss of the ability of
E1A to block GATA-1 activity and erythroid differentiation (4). Of note, this E1A mutant retained the critical amino
acids required for binding to p/CAF, which can also directly bind to E1A (34), suggesting that the effects of E1A are largely due to specific inhibition of CBP/p300 function. Since GATA-1-binding sites
in the locus control regions of the globin genes contribute to
maintaining DNase I hypersensitivity, this raised the possibility that
GATA-1 acts by recruiting CBP to the locus control regions, thereby
locally increasing histone acetylation. The results of the present
study suggest that the interaction between CBP and GATA-1 entails an
additional function, namely, acetylation of GATA-1 itself.
We demonstrated that CBP acetylates murine GATA-1 in vitro at two conserved lysine-rich motifs near the two zinc fingers. Using the CBP-related protein p300, Boyes et al. (7) mapped the major in vitro acetylation sites to the analogous motifs in chicken GATA-1, demonstrating the high degree of conservation between chicken and mouse GATA-1 in CBP- and p300-mediated acetylation.
Using anti-AK antibodies and in vivo labeling experiments we found that GATA-1 is acetylated in vivo, consistent with the findings of Boyes et al. (7). Using site-specific GATA-1 mutants, we further showed that acetylation in intact cells occurred at the same sites acetylated by CBP in vitro.
We also demonstrate that CBP can stimulate GATA-1 acetylation in vivo at the relevant sites and that expression of E1A abolishes acetylation completely. This demonstrates that CBP can strongly stimulate the acetylation of a transcription factor in vivo and that this activity is inhibited by E1A. These data further demonstrate that GATA-1 activity correlates well with its acetylation status (4).
While it is possible that other acetyltransferases such as SRC-1 and ACTR or unknown acetyltransferases acetylate GATA-1, several observations suggest that CBP is a major GATA-1 acetyltransferase. First, we have previously shown that CBP and GATA-1 associate in vivo; second, p/CAF does not acetylate GATA-1; third, there is remarkable specificity among different acetyltransferases regarding substrate and residue specificity (24, 36, 48).
To examine the mechanism by which CBP regulates GATA-1 activity, we
showed that in vitro acetylation did not detectably alter DNA binding
of either full-length GATA-1 or the zinc finger region alone.
Substitutions of lysine residues with arginine or alanine residues,
which maintain and neutralize the positive charge, respectively, did
not affect DNA-binding and dissociation rates of GATA-1 constructs expressed in mammalian cells, further supporting the lack of
involvement of the acetylated motifs in DNA binding. These findings are
consistent with the observation that GATA-1 mutants bearing a deletion
of the entire C terminus including the C-motif (
308) bind DNA
normally (25, 42). Furthermore, the solution nuclear
magnetic resonance spectroscopy structure of the C-terminal zinc finger
of chicken GATA-1 bound to DNA demonstrated that the site corresponding
to the C-terminal acetylation motif of murine GATA-1 does not make direct contact with DNA (29). Our findings contrast with
those of Boyes et al., who reported a significant change in DNA binding upon in vitro acetylation (7). These discrepancies might be the result of differences between chicken and mouse GATA-1 and between
CBP and p300. However, in agreement with our findings, mutations in the
chicken GATA-1 acetylation sites do not alter DNA binding
(7). Clearly, the strong acetylation-induced increase in DNA
binding of a peptide spanning the zinc finger region of chicken GATA-1
observed by Boyes et al. in vitro is not reflected in the moderate
stimulation of chicken GATA-1 activity by p300 in transient-activation
assays (7). It is possible that the in vitro conditions do
not reflect the actual changes in GATA-1 function triggered upon acetylation.
Sequence analysis of in vitro-acetylated peptides revealed that lysine 312 is the major acetylated residue in the C-motif while lysine 252 and lysine 246 are the predominant sites in the N-motif. Lysine 252, which is conserved among GATA-1 of different species, residues outside the canonical RXKK motif and might account for the residual acetylation observed in vitro with the NC-mut construct. We are in the process of testing the function of GATA-1 carrying a point mutation at this site. Nevertheless, even with lysine 252 intact, mutations at the N-motif lead to reduced acetylation and diminished biological function, indicating that the N-terminal acetylation motif is important.
While sequencing of acetylated synthetic peptides allows the identification of acetylation sites in the context of an intact amino acid sequence, i.e., without the potential artifacts which might result from the introduction of mutations, the results obtained by this method must be interpreted in the context of other experimental approaches. For example, we noted that acetylation of the peptide spanning the N-motif occurred with lower efficiency than did that of the peptide spanning the C-motif. However, when assayed in the context of full-length GATA-1, disruption of the C-motif reduced acetylation to only about half of that observed with wild-type GATA-1, indicating that the extents of acetylation at the N-motif and at the C-motif are comparable. Thus, sequences outside of the stretch of amino acids contained in the peptides might contribute to maximal acetylation efficiency, perhaps by increasing the binding affinity between GATA-1 and CBP.
In performing in vitro acetylation reactions, it is important to keep in mind that recombinant, purified acetyltransferases might display a substrate spectrum distinct from that observed in the presence of additional cofactors. For example, the recombinant purified yeast acetyltransferase Gcn5 acetylates only free histones but not histones packaged into nucleosomes (8). However, when assayed as a multicomponent complex, Gcn5 acetylates nucleosomal histones as well (for example, see reference 15). Therefore, cofactors bound to CBP or to GATA-1 might modulate the specificity and/or efficiency of the CBP acetyltransferase.
Transient-transfection experiments designed to test the functional role of acetylation showed that the C-motif but not the N-motif of GATA-1 is required for stimulation by CBP. Since the C-motif contributes to CBP binding, this suggests that physical association or subsequent acetylation or both are important for stimulating GATA-1 activity. Mutations in the C-motif do not interfere with acetylation at the N-motif in vitro (Fig. 2) or in vivo (Fig. 4), suggesting that the interaction between C-mut and CBP is sufficient for efficient catalysis. To address directly whether CBP-mediated acetylation is required for GATA-1 activation, we used two CBP mutants which lack HAT activity, one containing a point mutation and the other bearing a deletion in the HAT domain. Both constructs failed to acetylate GATA-1 and histones in vitro but activated GATA-1 with an efficiency comparable to that of wild-type CBP in transiently transfected NIH 3T3 cells. Together, these findings indicate that in transient-expression assays, acetylation of GATA-1 and histones by CBP is not required for GATA-1 stimulation. At least two explanations could account for this result. First, it is important to note that in transiently transfected nonerythroid cells with artificial reporter genes, CBP might stimulate GATA-1 activity by a mechanism different from that operational in erythroid cells with fully chromatinized GATA-1 target genes. The reporter gene used in the transient-transfection assays contains a single GATA site positioned closely to a TATA box. Therefore, in this setting, it is possible that CBP augments GATA-1 activity by serving as a link between GATA-1 and the basal transcription machinery. A functional domain analysis of CBP is being used to address this question. Second, it is possible that acetylation is mediated by p300/CBP-associated acetyltransferases, including ACTR (9) and SRC-1 (39, 47). Experiments are under way to test the role of the CBP-associated acetyltransferases during GATA-1 activation.
In performing similar transient-transfection experiments, Boyes et al. observed that a p300 mutant bearing a 50-aa deletion in the HAT domain failed to stimulate chicken GATA-1 activity (7). It is possible that such a deletion abrogated functions of p300 unrelated to its HAT activity.
While Boyes et al. did not test the function of the C-motif (the strongest acetylation site), mutations in the chicken GATA-1 N-motif resulted in a reduced response to p300, leading the authors to establish a correlation between chicken GATA-1 acetylation at the N-motif and transcriptional activation. Two open questions remain regarding this interpretation: first, the observed reduction in the p300 response is marginal (2.5-fold in wild-type GATA-1 compared to 1.4- and 1.9-fold in two acetylation mutants), especially in a transient-transfection assay. Second, the authors did not provide information about the acetylation status of these sites in vivo. In our experiments, mutations in the N-motif had no effect on DNA binding or transactivation by CBP in transient-transfection assays. Furthermore, binding of GATA-1 to a single GATA-1 site does not require the N-terminal zinc finger (25). Therefore, we believe that the mechanism by which the N-motif contributes to the GATA-1 function remains to be elucidated but is unlikely to involve regulation of DNA binding. In evaluating these findings, we point out that a biological function of the N-motif required the assay of GATA-1 constructs in erythroid cells with GATA-1-dependent genes present in their natural state (see below).
Since critical GATA-1 functions were uncovered only in maturing
erythroid cells (6, 41, 45), we used the GATA-1-deficient cell line G1E to study the functional role of the acetylation sites.
Mutations in either the N- or C-motif significantly reduced activity,
while mutations in both motifs abrogated activity entirely. Thus, only
in erythroid cells did we uncover a requirement for the N-motif.
Mutations in the N-motif did not interfere with binding to CBP or to
Fog (data not shown), the recently identified cofactor which
selectively binds to the N-terminal zinc finger of GATA-1 (41), excluding the possibility that mutations simply
disrupt the interaction of GATA-1 with its known cofactors. Deletion of the C terminus of GATA-1 leaving the C-motif intact (
331) resulted only in a small loss of activity, whereas a slightly larger deletion which removes the C-motif (
308) led to a much more pronounced loss
of function without affecting DNA binding. Together, these results
demonstrate that mutations in the acetylation motifs impair biological
activity without affecting DNA binding, which demonstrates that the
DNA-binding and acetylation functions can be uncoupled.
Interestingly, the ability of GATA-1 to induce megakaryocytic
conversion of the early myeloid cell line 416B also depends in part on
an intact C-motif (42). In these assays,
308 was significantly less active than
331, which raises the possibility that CBP also synergizes with GATA-1 in the regulation of
megakaryocytic gene expression. Together, these results indicate that
the C-terminal acetylation site is of great biological importance and
are consistent with a requirement of CBP for GATA-1 function in vivo.
Acetylation of lysine residues neutralizes their positive charge and changes the size of the residue. In general, such changes could conceivably entail alterations in protein function similar to those incurred upon phosphorylation. For example, acetylation could lead to changes in protein conformation. Such a mechanism has been proposed for p53, where acetylation in the regulatory domain leads to increased DNA-binding activity (16). Alternatively, acetylation could directly influence protein-DNA interactions, as has been suggested for binding of histone tails to DNA, or it could affect protein-protein interactions, as described for binding of histone tails to the yeast transcriptional repressor Tup1 (13).
The mechanism by which either acetylation motif in GATA-1 exerts its function in G1E cells remains to be determined. Gel shift analysis with nuclear extracts of the virally infected G1E cells demonstrated the presence of equal amounts of DNA-bound GATA-1 proteins, and immunofluorescence microscopy confirmed the nuclear localization of all constructs. This suggests that acetylation in either motif does not regulate nuclear localization, DNA binding, or protein stability. Several additional mechanisms by which acetylation regulates GATA-1 activity could be envisioned. It is conceivable that acetylation leads to a conformational change in GATA-1, resulting in increased activity through exposure of an activation domain. Alternatively, the acetylation motifs might represent docking sites for still unidentified coactivators or repressors, and acetylation might positively or negatively regulate their binding affinity. More extensive studies, including structural analyses, will be required to determine the mechanistic role of GATA-1 acetylation.
| |
ACKNOWLEDGMENTS |
|---|
We thank Merlin Crossley, Colyn Crane-Robinson, Warren Pear, Marc Montminy, and Michael Rosenfeld for providing plasmids, antibodies, and cell lines. We are grateful to Dawn Eastmond and Toshio Asakura for assistance with HPLC separation of GATA-1 peptides. Peptide synthesis and protein-sequencing services were provided by the Protein Chemistry Laboratory of the Medical School of the University of Pennsylvania. We thank Margaret Chou, Merlin Crossley, Stuart Orkin, and Morty Poncz for helpful suggestions and for critically reading the manuscript.
This work was supported by the Baldasare Award (G.A.B.), the American Society of Hematology Scholar Award (G.A.B.) and the Cooley's Anemia Foundation (G.A.B.). Services provided by the Protein Chemistry Laboratory of the Medical School of the University of Pennsylvania were supported by core grants of the Diabetes and Cancer Centers (DK-19525 and CA-16520).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Abramson Pediatric Research Center no.316A, The Children's Hospital of Philadelphia, 34th St. and Civic Center Blvd., Philadelphia, PA 19104. Phone: (215) 590-3988. Fax: (215) 590-4834. E-mail: blobel{at}emailchop.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Abraham, S. E., S. Lobo, P. Yaciuk, H. G. Wang, and E. Moran. 1993. p300, and p300-associated proteins, are components of TATA-binding protein (TBP) complexes. Oncogene 8:1639-1647[Medline]. |
| 2. |
Allfrey, V.,
R. M. Faulkner, and A. E. Mirsky.
1964.
Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis.
Proc. Natl. Acad. Sci. USA
51:786-794 |
| 3. | Bannister, A. J., and T. Kouzarides. 1996. The CBP co-activator is a histone acetyltransferase. Nature 384:641-643[Medline]. |
| 4. |
Blobel, G. A.,
T. Nakajima,
R. Eckner,
M. Montminy, and S. H. Orkin.
1998.
CREB-binding protein (CBP) cooperates with transcription factor GATA-1 and is required for erythroid differentiation.
Proc. Natl. Acad. Sci. USA
95:2061-2066 |
| 5. | Blobel, G. A., C. A. Sieff, and S. H. Orkin. 1995. Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Mol. Cell. Biol. 15:3147-3153[Abstract]. |
| 6. | Blobel, G. A., M. C. Simon, and S. H. Orkin. 1995. Rescue of GATA-1-deficient embryonic stem cells by heterologous GATA-binding proteins. Mol. Cell. Biol. 15:626-633[Abstract]. |
| 7. | Boyes, J., P. Byfield, Y. Nakatani, and V. Ogryzko. 1998. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396:594-598[Medline]. |
| 8. | Brownell, J. E., J. Zhou, T. Ranalli, R. Kobayashi, D. G. Edmondson, S. Y. Roth, and C. D. Allis. 1996. Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 84:843-851[Medline]. |
| 9. | Chen, H., R. J. Lin, R. L. Schiltz, D. Chakravarti, A. Nash, L. Nagy, M. L. Privalsky, Y. Nakatani, and R. M. Evans. 1997. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569-580[Medline]. |
| 10. |
Cho, H.,
G. Orphanides,
X. Sun,
X. J. Yang,
V. Ogryzko,
E. Lees,
Y. Nakatani, and D. Reinberg.
1998.
A human RNA polymerase II complex containing factors that modify chromatin structure.
Mol. Cell. Biol.
18:5355-5363 |
| 11. | Crossley, M., M. Merika, and S. H. Orkin. 1995. Self-association of the erythroid transcription factor GATA-1 mediated by its zinc finger domains. Mol. Cell. Biol. 15:2448-2456[Abstract]. |
| 12. | Dallas, P. B., P. Yaciuk, and E. Moran. 1997. Characterization of monoclonal antibodies raised against p300: both p300 and CBP are present in intracellular TBP complexes. J. Virol. 71:1726-1731[Abstract]. |
| 13. |
Edmondson, D. G.,
M. M. Smith, and S. Y. Roth.
1996.
Repression domain of the yeast global repressor Tup1 interacts directly with histone H3 and H4.
Genes Dev.
10:1247-1259 |
| 14. |
Fujiwara, Y.,
C. P. Browne,
K. Cunniff,
S. C. Goff, and S. H. Orkin.
1996.
Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1.
Proc. Natl. Acad. Sci. USA
93:12355-12358 |
| 15. |
Grant, P. A.,
L. Duggan,
J. Cote,
S. M. Roberts,
J. E. Brownell,
R. Candau,
R. Ohba,
T. Owen-Hughes,
C. D. Allis,
F. Winston,
S. L. Berger, and J. L. Workman.
1997.
Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones:characterization of an Ada complex and the SAGA (Spt/Ada) complex.
Genes Dev.
11:1640-1650 |
| 16. | Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606[Medline]. |
| 17. |
Hebbes, T. R.,
A. L. Clayton,
A. W. Thorne, and C. Crane-Robinson.
1994.
Core histone hyperacetylation co-maps with generalized DNase I sensitivity in the chicken -globin chromosomal domain.
EMBO J.
13:1823-1830[Medline].
|
| 18. | Hebbes, T. R., C. H. Turner, A. W. Thorne, and C. Crane-Robinson. 1989. A "minimal epitope" anti-protein antibody that recognises a single modified amino acid. Mol. Immunol. 26:865-873[Medline]. |
| 19. | Imhof, A., X. J. Yang, V. V. Ogryzko, Y. Nakatani, A. P. Wolfe, and H. Ge. 1997. Acetylation of general transcription factors by histone acetyltransferases. Curr. Biol. 7:689-692[Medline]. |
| 20. | Kamei, Y., L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S. Lin, R. A. Heyman, D. Rose, C. K. Glass, and M. G. Rosenfeld. 1996. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414[Medline]. |
| 21. |
Kee, B.,
J. Arias, and M. Montminy.
1996.
Adaptor mediated recruitment of RNA polymerase II to a signal dependent activator.
J. Biol. Chem.
271:2373-2375 |
| 22. |
Korzus, E.,
J. Torchia,
D. W. Rose,
L. Xu,
R. Kurokawa,
E. M. McInerney,
T.-M. Mullen,
C. K. Glass, and M. G. Rosenfeld.
1998.
Transcription factor-specific requirements for coactivators and their acetyltransferase functions.
Science
279:703-707 |
| 23. | Kwok, R. P., J. R. Lunblad, J. C. Chrivia, J. P. Richards, H. P. Bachinger, R. G. Brennan, S. G. Roberts, M. R. Green, and R. H. Goodman. 1994. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370:223-226[Medline]. |
| 24. | Li, Q., M. Herrler, N. Landsberger, N. Kaludov, V. V. Ogryzko, Y. Nakatani, and A. P. Wolffe. 1998. Xenopus NF-Y pre-sets chromatin to potentiate p300 and acetylation-responsive transcription from the Xenopus hsp70 promoter in vivo. EMBO J. 17:6300-6315[Medline]. |
| 25. |
Martin, D. I., and S. H. Orkin.
1990.
Transcriptional activation and DNA binding by the erythroid factor GF-1/NF-E1/Eryf1.
Genes Dev.
4:1886-1898 |
| 26. | Martinez-Balbas, M., A. Bannister, K. Martin, P. Haus-Seuffert, M. Meisternst, and T. Kouzarides. 1998. The acetyltransferase activity of CBP stimulates transcription. EMBO J. 17:2886-2893[Medline]. |
| 27. | Nakajima, T., C. Uchida, S. F. Anderson, C.-G. Lee, J. Hurwitz, J. D. Parvin, and M. Montminy. 1997. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90:1107-1112[Medline]. |
| 28. | Ogryzko, V. V., L. R. Schiltz, V. Russanova, B. H. Howard, and Y. Nakatani. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959[Medline]. |
| 29. |
Omichinsky, J. G.,
G. M. Clore,
O. Schaad,
G. Felsenfeld,
C. Trainor,
E. Appella,
S. J. Stahl, and A. M. Gronenborn.
1993.
NMR structure of a specific DNA complex of Zn-containing DNA binding domain of GATA-1.
Science
261:438-446 |
| 30. |
Orkin, S. H.
1992.
GATA-binding transcription factors in hematopoietic cells.
Blood
80:575-581 |
| 31. | Pazin, M. J., and J. T. Kadonaga. 1997. What's up and down with histone deacetylation and transcription. Cell 89:325-328[Medline]. |
| 32. |
Pear, W. S.,
G. P. Nolan,
M. L. Scott, and D. Baltimore.
1993.
Production of high-titer helper-free retroviruses by transient transfection.
Proc. Natl. Acad. Sci. USA
90:8392-8396 |
| 33. |
Pogo, P. G. T.,
V. G. Allfrey, and A. E. Mirsky.
1966.
RNA synthesis and histone acetylation during the course of gene activation in lymphocytes.
Proc. Natl. Acad. Sci. USA
55:805-812 |
| 34. | Reid, J. L., A. J. Bannister, P. Zegerman, M. A. Martinez-Balbas, and T. Kouzarides. 1998. E1A directly binds and regulates the P/CAF acetyltransferase. EMBO J. 17:4469-4477[Medline]. |
| 35. | Roth, S. Y., and C. D. Allis. 1996. Histone acetylation and chromatin assembly: a single escort, multiple dances? Cell 87:5-8[Medline]. |
| 36. |
Sakaguchi, K.,
J. E. Herrera,
S. Saito,
T. Miki,
M. Bustin,
A. Vassilev,
C. W. Anderson, and E. Appella.
1998.
DNA damage activates p53 through a phosphorylation-acetylation cascade.
Genes Dev.
12:2831-2841 |
| 37. | Sang, N., M. L. Avantaggiati, and A. Giordano. 1997. Roles of p300, pocket proteins, and hTBP in E1A-mediated transcriptional regulation and inhibition of p53 transactivation activity. J. Cell. Biochem. 66:277-285[Medline]. |
| 38. | Shikama, N., J. Lyon, and N. B. LaThangue. 1997. The p300/CBP family: integrating signals with transcription factors and chromatin. Trends Cell Biol. 7:230-236. |
| 39. | Spencer, T. E., G. Jenster, M. M. Burcin, C. D. Allis, J. Zhou, C. A. Mizzen, N. J. McKenna, S. A. Onate, S. Y. Tsai, M. J. Tsai, and B. W. O'Malley. 1997. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194-198[Medline]. |
| 40. |
Swope, D. L.,
C. L. Mueller, and J. C. Chrivia.
1996.
CREB-binding protein activates transcription through multiple domains.
J. Biol. Chem.
271:28138-28145 |
| 41. | Tsang, A. P., E. Visvader, C. A. Turner, Y. Fujiwara, C. Yu, M. J. Weiss, M. Crossley, and S. H. Orkin. 1997. FOG, a multitype zinc finger protein, acts as a cofactor for transcription factor GATA-1 in erythroid and megakaryocytic differentiation. Cell 90:109-119[Medline]. |
| 42. | Visvader, J. E., M. Crossley, J. Hill, and S. H. Orkin. 1995. The C-terminal zinc finger of GATA-1 or GATA-2 is sufficient to induce differentiation of an early myeloid cell line. Mol. Cell. Biol. 15:634-641[Abstract]. |
| 43. |
Weiss, M. J.,
G. Keller, and S. H. Orkin.
1994.
Novel insights into erythroid development revealed through in vitro differentiation of GATA-1 embryonic stem cells.
Genes Dev.
8:1184-1197 |
| 44. |
Weiss, M. J., and S. H. Orkin.
1995.
Transcription factor GATA-1 permits survival and maturation of erythroid precursors by preventing apoptosis.
Proc. Natl. Acad. Sci. USA
92:9623-9627 |
| 45. | Weiss, M. J., C. Yu, and S. H. Orkin. 1997. Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene targeted cell line. Mol. Cell. Biol. 17:1642-1651[Abstract]. |
| 46. | Yang, X.-J., V. V. Ogryzko, J. Nishikawa, B. H. Howard, and Y. Nakatani. 1996. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382:319-324[Medline]. |
| 47. |
Yao, T.-P.,
G. Ku,
N. Zhou,
R. Scully, and D. M. Livingston.
1996.
The nuclear hormone receptor coactivator SRC-1 is a specific target of p300.
Proc. Natl. Acad. Sci. USA
93:10626-10631 |
| 48. |
Zhang, W., and J. J. Bieker.
1998.
Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases.
Proc. Natl. Acad. Sci. USA
95:9855-9860 |
This article has been cited by other articles: